Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately
MWN-AI** Summary
Mereo BioPharma Group PLC (NASDAQ: MREO) has recently faced significant legal challenges following a dramatic collapse in its stock value, which has led to a class action lawsuit filed by Wolf Haldenstein Adler Freeman & Herz LLP. The lawsuit pertains to shareholders who acquired Mereo American Depositary Shares (ADS) between June 5, 2023, and December 26, 2025. Investors are urged to contact the law firm immediately, particularly those who lost funds due to the alleged misleading statements made by Mereo concerning the prospects of its Phase 3 clinical trials for setrusumab, a treatment aimed at Osteogenesis Imperfecta (OI).
Investors claim that Mereo executives expressed unwarranted optimism regarding the likelihood of achieving statistical significance in the trials, which were critical for the company's future and potential regulatory approval. These assertions were made despite underlying adverse conditions that suggested the trials were not on track to meet their primary endpoints. On December 29, 2025, Mereo disclosed that the trials had failed to demonstrate the expected reduction in annualized fracture rates, leading to a shocking drop in share price from $2.31 to $0.29 within a single trading session – a staggering loss of over 87% for shareholders.
Shareholders looking to seek recourse have until April 6, 2026, to file motions for lead plaintiff appointments in the class action lawsuit. Wolf Haldenstein, with over 125 years of experience in securities litigation, is dedicated to fighting for the rights of investors harmed by misrepresentation. Affected shareholders or those with relevant information are encouraged to reach out to the firm for assistance.
MWN-AI** Analysis
Shareholders who invested in Mereo BioPharma Group PLC (NASDAQ: MREO) and experienced financial losses should consider taking immediate action. The recent filing of a class action lawsuit against Mereo, alleging misleading statements regarding the success of its Phase 3 clinical trials for setrusumab, highlights the potential for recovery for affected investors. The lawsuit covers all individuals who purchased Mereo American Depositary Shares between June 5, 2023, and December 26, 2025, during a period when confidence in the company's clinical outcomes was systematically misrepresented.
Following disappointing trial results reported on December 29, 2025, Mereo’s share price plummeted by over 87%, collapsing from $2.31 to just $0.29 in a single trading session. This dramatic decrease illustrates the significant impact that false assurances regarding clinical success can have on investor confidence and market valuation. The allegations suggest that Mereo had not only failed to meet critical efficacy endpoints but also misled investors regarding the viability of its treatments.
Investors who sustained losses during the specified period are encouraged to contact Wolf Haldenstein Adler Freeman & Herz LLP, a firm with extensive experience in securities litigation. With over 125 years in legal practice, they are well-positioned to help affected shareholders seek justice and potentially recover their losses. Investors have until April 6, 2026, to take steps to become the lead plaintiff, which could provide them with a pivotal role in the proceedings.
For those affected by Mereo’s significant stock decline, the opportunity to pursue legal action represents a potential avenue for compensation. Interested shareholders should not hesitate to reach out to Wolf Haldenstein for further guidance on this matter.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Lead Plaintiff Deadline is April 6, 2026
NEW YORK, Feb. 14, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group PLC (NASDAQ: MREO) ("Mereo" or the "Company") inclusive on behalf of all persons and entities that purchased or otherwise acquired Mereo American Depositary Shares ("ADS's") between June 5, 2023 and December 26, 2025, both dates inclusive (the "Class Period"). Investors have until April 6, 2026, to seek appointments as lead plaintiff.
PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION
Investors allege that Mereo and certain executives made materially false and misleading statements about the likelihood of success of its Phase 3 clinical trials for setrusumab, a treatment for Osteogenesis Imperfecta (OI).
Specifically, defendants repeatedly expressed confidence that:
- The ORBIT and COSMIC Phase 3 trials would
- Achieve statistical significance in reducing annualized fracture rates (AFR)
- Position setrusumab for regulatory success
While promoting these optimistic projections, the complaint claims the company concealed adverse facts showing:
- Neither Phase 3 study was on track to meet its primary endpoint
- The trials ultimately failed to demonstrate AFR reduction versus control groups
Corrective Disclosure & Stock Collapse
On December 29, 2025, Mereo issued a press release revealing that:
- Neither ORBIT nor COSMIC achieved statistical significance
- The primary endpoint — reduction in AFR — was not met
- Improvements in bone mineral density did not offset failure of core efficacy goals
Following this disclosure:
- Share price fell from $2.31 to $0.29 in one trading session
- Representing a loss of over 87% of shareholder value
Investors seeking appointment as Lead Plaintiff may file a motion with the court no later than April 6, 2026.
Why Wolf Haldenstein Adler Freeman & Herz LLP?:
This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.
We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.
Contact:
- Phone: (800) 575-0735 or (212) 545-4774
- Email: classmember@whafh.com
- Contact Person: Gregory Stone, Director of Case and Financial Analysis
Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Wolf Haldenstein Adler Freeman & Herz LLP
FAQ**
How did the alleged false and misleading statements about Mereo BioPharma Group MREO's Phase 3 clinical trials impact shareholders financially during the class period from June 5, 2023, to December 26, 2025?
What specific adverse facts were concealed by Mereo BioPharma Group MREO regarding the outcomes of the ORBIT and COSMIC trials, and how did these disclosures affect investor confidence?
Following the significant drop in share price from $2.to $0.29 on December 29, 2025, what steps can affected shareholders take to seek restitution through Wolf Haldenstein's class action lawsuit?
What evidence do investors need to provide to support their claims against Mereo BioPharma Group MREO in order to be eligible for lead plaintiff status by the April 6, 2026 deadline?
**MWN-AI FAQ is based on asking OpenAI questions about Mereo BioPharma Group (NASDAQ: MREO).
NASDAQ: MREO
MREO Trading
2.58% G/L:
$0.4059 Last:
529,176 Volume:
$0.3895 Open:
